SkinBioTherapeutics (LON:SBTX) Announces Earnings Results

SkinBioTherapeutics (LON:SBTX) issued its quarterly earnings results on Monday. The company reported GBX (0.31) earnings per share (EPS) for the quarter, Digital Look Earnings reports. The business had revenue of GBX 217 million for the quarter. SkinBioTherapeutics had a negative return on equity of 10.01% and a negative net margin of 15.01%.

SkinBioTherapeutics Price Performance

SBTX stock opened at GBX 8.37 on Tuesday. The company has a market capitalization of £21.69 million, a P/E ratio of -27.00 and a beta of 0.47. SkinBioTherapeutics has a twelve month low of GBX 5 and a twelve month high of GBX 23. The business has a 50 day simple moving average of GBX 9.75 and a 200-day simple moving average of GBX 12.75. The company has a current ratio of 4.84, a quick ratio of 10.01 and a debt-to-equity ratio of 10.55.

SkinBioTherapeutics Company Profile

SkinBioTherapeutics plc, a life science company, engages in identification and development of technology that harnesses the human microbiome to improve health in the United Kingdom, the United States, and Europe. It develops SkinBiotix technology that promotes skin health by harnessing the beneficial properties of probiotic bacteria and the active components; and AxisBiotix technology that focuses on the gut-skin relationship and is designed to alleviate the symptoms associated with psoriasis. The company has an agreement with Croda Plc; and operates two research programmes with the University of Manchester, an oral programme and an inflammation study.